CTRI/2018/04/013405
Completed
未知
Randomised Controlled Trial Comparing efficacy of Pidotimod versus placebo in addition to inhaled corticosteroid therapy in children with persistent asthma. - PIDO
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Children between 5-12years of age with persistent asthma requiring inhaled corticosteroid therapy
- Sponsor
- Postgraduate Institute Of Medical Education and Research
- Enrollment
- 79
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed children (5\-12 years old) with persistent asthma defined as per Global Initiative for Asthma guideline \[ diagnosis is made in children with history of variable respiratory symptoms i.e, wheeze, cough, shortness of breath, chest tightness atleast \>twice/week symptoms, \>3\-4/month nocturnal symptoms, frequent ER visits for asthma and documented expiratory airflow limitation i.e. FEV1 or PEFR \<80% of predicted, FEV1/FVC \<80% and PEFR variability \>20 which improve upon bronchodilator challenge after adequately ruling out acute and chronic conditions that mimic asthma]
Exclusion Criteria
- •1\. Children who have received asthma preventer therapy (i.e. inhaled corticosteroids or any preventer therapy), for any duration \>2 weeks, during the preceding six months.
- •2\. Children suffering from other diseases that can cause wheezing or difficulty breathing viz cystic fibrosis, and chronic lung disease.
- •3\. Children with congenital lung dysplasia;
- •4\. Children with previously diagnosed severe renal failure.
- •5\. Children with autoimmune, or immunodeficiency disorders.
- •6\. Children who have been prescribed any immunomodulator therapy for any condition in the past.
- •7\. Children whose parents are unwilling or unable to adhere to the follow up protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinsonâ??s Disease- A Pilot study.Health Condition 1: G20- Parkinsons diseaseCTRI/2019/02/017634Sun Pharmaceutical Industries Ltd
Completed
Phase 3
Randomized Controlled Trial Comparing Efficacy of Sorafenib versus Sorafenib In combination with Low dose cisplatin /fluorouracil hepatic arterial InfUSion chemotherapy in Patients with Advanced Hepatocellular Carcinoma(SILIUS Phase III)HCCJPRN-UMIN000004315SILIUS Trial Group,Japan Ministry of Health, Labour and Welfare190
Not yet recruiting
Not Applicable
Comparison of efficacy of two insulin regimens in Patients of Acute Stroke with hyperglycemiaHealth Condition 1: I639- Cerebral infarction, unspecifiedCTRI/2019/03/017919Smruti Babtiwale
Not yet recruiting
Phase 3
Treatment of COVID19 : A randomised controlled trialHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseasesCTRI/2020/04/024904Director General Armed Forces Medical Services
Completed
Phase 2
Add-on homoeopathic treatment of COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/12/029668Central Council for Research in Homoeopathy